Download PDF

1. Company Snapshot

1.a. Company Description

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China.The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands.


As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China.The company was founded in 2005 and is headquartered in Taizhou, China.

Show Full description

1.b. Last Insights on SXTC

China SXT Pharmaceuticals' recent performance was hindered by a prolonged period of non-compliance with Nasdaq's minimum bid price requirement, which was resolved on March 13, 2025. The company's stock price volatility and failure to meet the listing rule's threshold led to a deficiency, but it has since regained compliance. Additionally, the company's recent earnings release was not available, but its financial performance has been impacted by the ongoing market volatility and intense competition in the traditional Chinese medicine market.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

Mar -17

Source: globenewswire.com

Card image cap

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Feb -21

Source: globenewswire.com

Card image cap

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Oct -07

Source: globenewswire.com

Card image cap

China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule

Oct -26

Source: globenewswire.com

Card image cap

China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split

Oct -04

Source: globenewswire.com

Card image cap

Why Is China SXT Pharmaceuticals (SXTC) Stock Up 24% Today?

Sep -07

Source: investorplace.com

Card image cap

Why Is China SXT Pharmaceuticals (SXTC) Stock Up 110% Today?

Aug -21

Source: InvestorPlace

Card image cap

China SXT Pharmaceuticals (SXTC) Stock: 1-For-20 Reverse Split Goes Into Effect

May -19

Source: Pulse2

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.40%)

6. Segments

Regular Traditional Chinese Medicine Pieces

Expected Growth: 12.4%

Growing demand for natural and herbal remedies, increasing adoption of traditional Chinese medicine, and rising health awareness drive the growth of the traditional Chinese medicine pieces market.

Advanced Traditional Chinese Medicine Pieces

Expected Growth: 12.4%

Growing demand for holistic wellness, increasing adoption of traditional Chinese medicine, and advancements in technology integrating ancient practices with modern innovations drive the growth of Advanced Traditional Chinese Medicine Pieces from China SXT Pharmaceuticals, Inc.

Raw Medicinal Materials

Expected Growth: 12.4%

Growing demand for traditional Chinese medicine, increasing adoption in Western markets, and China's large supply of raw medicinal materials drive growth in this segment.

Fine Traditional Chinese Medicine Pieces

Expected Growth: 12.4%

Growing demand for natural remedies, increasing adoption of traditional Chinese medicine, and expanding distribution channels drive the growth of Fine Traditional Chinese Medicine Pieces from China SXT Pharmaceuticals, Inc.

7. Detailed Products

Penicillin G Sodium

An antibiotic used to treat bacterial infections such as pneumonia, meningitis, and septicemia.

Cephalexin

A cephalosporin antibiotic used to treat bacterial infections such as pneumonia, skin infections, and urinary tract infections.

Cefaclor

A cephalosporin antibiotic used to treat bacterial infections such as pneumonia, bronchitis, and skin infections.

Tetracycline

A broad-spectrum antibiotic used to treat bacterial infections such as acne, cholera, and brucellosis.

Vitamin D3

A dietary supplement used to prevent and treat vitamin D deficiency.

Vitamin B12

A dietary supplement used to prevent and treat vitamin B12 deficiency.

8. China SXT Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for China SXT Pharmaceuticals, Inc. is medium due to the presence of alternative pharmaceutical products in the market.

Bargaining Power Of Customers

The bargaining power of customers for China SXT Pharmaceuticals, Inc. is low due to the company's strong brand reputation and customer loyalty.

Bargaining Power Of Suppliers

The bargaining power of suppliers for China SXT Pharmaceuticals, Inc. is medium due to the presence of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants for China SXT Pharmaceuticals, Inc. is high due to the growing demand for pharmaceutical products and the relatively low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry for China SXT Pharmaceuticals, Inc. is high due to the presence of several established players in the market, leading to intense competition.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 20.36%
Debt Cost 9.42%
Equity Weight 79.64%
Equity Cost 9.42%
WACC 9.42%
Leverage 25.57%

11. Quality Control: China SXT Pharmaceuticals, Inc. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Embecta

A-Score: 5.5/10

Value: 8.2

Growth: 1.7

Quality: 6.2

Yield: 7.0

Momentum: 7.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
YS Biopharma

A-Score: 4.5/10

Value: 8.8

Growth: 4.6

Quality: 5.9

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Bionomics

A-Score: 3.6/10

Value: 3.9

Growth: 3.9

Quality: 8.2

Yield: 0.0

Momentum: 4.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Qilian International Holding

A-Score: 3.3/10

Value: 7.5

Growth: 3.0

Quality: 3.4

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
InterCure

A-Score: 3.1/10

Value: 9.0

Growth: 2.3

Quality: 2.9

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
China SXT Pharmaceuticals

A-Score: 3.0/10

Value: 8.0

Growth: 3.3

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.41$

Current Price

1.41$

Potential

-0.00%

Expected Cash-Flows